180 Life Sciences Corp. (ATNF)
$
7.04
-0.57 (-8.10%)
Key metrics
Financial statements
Free cash flow per share
-0.5534
Market cap
1.1 Billion
Price to sales ratio
11.3 Thousand
Debt to equity
0.2625
Current ratio
0.5797
Income quality
0.3432
Average inventory
0
ROE
-1.4124
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
1180 Life Sciences Corp. is a clinical-stage biotechnology company focused on addressing unmet medical needs related to chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company has several product development platforms, including its fibrosis and anti-tumor necrosis factor (anti-TNF) platform, currently in Phase IIb clinical trials, targeting conditions related to fibrosis and Anti-TNF treatment. Additionally, the Synthetic Cannabidiol (CBD) Analogs platform is under preclinical trials, featuring synthetic derivatives of CBD, while the a7nAChR platform, designed for immune suppression, is also in preclinical trials, focusing on the alpha 7 nicotinic acetylcholine receptor. The company incurred an interest expense of $50,640.00 reflecting its debt servicing obligations. The operating income ratio is 0.00 indicating the company's operational profitability margin. The total costs and expenses for the company are $6,324,729.00 reflecting its overall spending. Moreover, the company reported depreciation and amortization expenses of $190,112.00 illustrating the wear and tear of its assets. The EBITDA ratio is 0.00 highlighting the company's operational efficiency. In terms of its market positioning, the stock is affordable at $0.90 making it suitable for budget-conscious investors. The stock also enjoys a high average trading volume of 8,403,143.00 indicating strong liquidity and interest from investors. With a market capitalization of $1,077,345,280.00 the company is classified as a small-cap player, which may offer unique investment opportunities. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and demonstrating its potential for growth. Furthermore, it belongs to the Healthcare sector, driving innovation and advancement within its field.
Analysts predict 180 Life Sciences Corp. stock to fluctuate between $0.66 (low) and $17.75 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-08-15, 180 Life Sciences Corp.'s market cap is $1,077,345,280, based on 153,032,000 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, 180 Life Sciences Corp. has a Lower Market-Cap, indicating a difference in performance.
To buy 180 Life Sciences Corp. (ATNF) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATNF. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
180 Life Sciences Corp.'s last stock split was 1:19 on 2024-02-28.
Revenue: $0 | EPS: -$15.49 | Growth: -70.55%.
Visit https://180lifesciences.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $3,382 (2021-08-09) | All-time low: $0.66 (2025-04-09).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif. , Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase price of $2.65 per share.
prnewswire.com
180 Life Sciences announces entry into PIPE funding documents to raise $425 million in gross proceeds to launch next generation Ethereum treasury strategy and planned rebranding to ETHZilla PALO ALTO, Calif. , July 29, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF) (the "Company" or "180 Life Sciences") today announced that it plans to adopt a treasury policy under which the principal holding in its treasury reserve will be Ether ("ETH"), the native digital asset of Ethereum.
accessnewswire.com
PALO ALTO, CA / ACCESS Newswire / July 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180" or the "Company), an innovative biotechnology company that is currently pivoting to the global iGaming sector, today announced two significant value enhancements to its existing, legacy intellectual property ("IP") portfolio-reinforcing part of the Company's strategy relating to continuing to build shareholder value through scientific innovation and patent protection for legacy IP assets. These new developments reflect 180's ongoing efforts to secure strong IP rights for its novel IP, while also positioning these assets for potential future partnering, licensing, or strategic transactions aimed at maximizing value for shareholders while the Company focuses on the global iGaming sector.
accessnewswire.com
PALO ALTO, CA / ACCESS Newswire / May 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), an innovative media and entertainment company focused on the global iGaming sector, with certain legacy biotechnology intellectual property assets, today announced that the United States Patent and Trademark Office ("USPTO") has issued an official Notice of Allowance for U.S. Patent Application No. 17/556,584, covering a novel method for preventing or reducing Post-Operative Cognitive Dysfunction ("POCD").
accessnewswire.com
PALO ALTO, CALIFORNIA / ACCESS Newswire / April 30, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences," the "Company," "we," or "us") today announced that it has entered into a Settlement and Mutual Release Agreement (the "Agreement") with Elray Resources, Inc. ("Elray") and Luxor Capital, LLC ("Luxor"). The Agreement strengthens and simplifies the Company's capital structure through a significant repurchase of shares.
accesswire.com
PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 1,200,000 shares of common stock.
accesswire.com
PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr.
accesswire.com
PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024. Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning.
accesswire.com
PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately.
accesswire.com
PALO ALTO, CA / ACCESSWIRE / October 16, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF)("180" or the "Company"), today released the following letter to stockholders from its Interim Chief Executive Officer, Blair Jordan. Dear Stockholders: We are excited to announce that 180 is planning to strategically enter into the online gaming industry, utilizing its newly acquired "back-end" gaming platform, which incorporates blockchain technology and full cryptocurrency operability (the "Gaming Technology Platform").
See all news